KfH-Nierenzentrum / KfH Kidney Centre
Hospital
Location:
München,
Germany (DE)
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial (2025)
Marx N, Deanfield JE, Mann JF, Arechavaleta R, Bain SC, Bajaj HS, Bayer Tanggaard K, et al.
Journal article
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (2025)
McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, Mann JF, et al.
Journal article
Relationship between age at initiation of cysteamine treatment, adherence with therapy, and glomerular kidney function in infantile nephropathic cystinosis (2022)
Nießl C, Boulesteix AL, Oh J, Palm K, Schlingmann P, Wygoda S, Haffner D, et al.
Journal article
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial (2022)
Waijer SW, Vart P, Cherney DZ, Chertow GM, Jongs N, Langkilde AM, Mann JFE, et al.
Journal article